Position in QNCX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
-$58,754,060 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2021
2 quarters on record
Derivatives in QNCX
reported options exposure · as of Mar 31, 2026CallValue
$4,444,000
CallShares
220,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026TUDOR INVESTMENT CORP ET AL holds $333,275,952 across 117 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
462,588 | $53,114,354 | |
| 2 | RPRX |
Royalty Pharma plc
|
671,680 | $32,220,489 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
495,591 | $28,818,616 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
650,000 | $26,149,500 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
267,520 | $14,103,654 | |
| 6 | FOLD |
AMICUS THERAPEUTICS, INC.
|
900,000 | $13,014,000 | |
| 7 | ABVX |
Abivax S.A.
|
101,611 | $11,314,384 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
87,852 | $8,543,607 |
All Filings in QNCX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,444,000 | 220,000 | Call | Defined | 2026-05-15 | |
| 2021-09-30 | $58,754,060 | 3,205 | Shares | Defined | 2021-11-17 | |
| No filing history on record for this holder in this stock. | ||||||